Cancer cell stemness, responses to experimental genotoxic treatments, cytomegalovirus protein expression and DNA replication stress in pediatric medulloblastomas

References

• Yi Y, Hsieh IY, Huang X, et al. Glioblastoma stem-like cells: characteristics, microenvironment, and therapy. Front Pharmacol. 2016;7:477.
   PubMed Web of Science ®Google Scholar
• Burrell RA, McClelland SE, Endesfelder D, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013;494:492–496.
   PubMed Web of Science ®Google Scholar
• Harkins L, Volk AL, Samanta M, et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet. 2002;360:1557–1563.
   PubMed Web of Science ®Google Scholar
• Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170:998–1002.
   PubMed Web of Science ®Google Scholar
• Harkins LE, Matlaf LA, Soroceanu L, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae. 2010;1:8.
   PubMedGoogle Scholar
• Taher C, Frisk G, Fuentes S, et al. High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers. Transl Oncol. 2014;7:732–740.
   PubMed Web of Science ®Google Scholar
• Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347–3350.
   PubMed Web of Science ®Google Scholar
• Rahbar A, Orrego A, Peredo I, et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol. 2013;57:36–42.
   PubMed Web of Science ®Google Scholar
• Bartek J Jr., Fornara O, Merchut-Maya JM, et al. Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas. Mol Oncol. 2017;11:945–964.
   PubMed Web of Science ®Google Scholar
• Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121:4043–4055.
   PubMed Web of Science ®Google Scholar
• Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–1355.
   PubMed Web of Science ®Google Scholar
• Kanu N, Cerone MA, Goh G, et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 2016;17:185.
   PubMed Web of Science ®Google Scholar
• Lugli N, Sotiriou SK, Halazonetis TD. The role of SMARCAL1 in replication fork stability and telomere maintenance. DNA Repair (Amst). 2017;56:129–134.
   PubMed Web of Science ®Google Scholar
• Galanos P, Vougas K, Walter D, et al. Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nat Cell Biol. 2016;18:777–789.
   PubMed Web of Science ®Google Scholar
• Galanos P, Pappas G, Polyzos A, et al. Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability. Genome Biol. 2018;19:37.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870.
   PubMed Web of Science ®Google Scholar
• Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–913.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, et al. ATM activation in normal human tissues and testicular cancer. Cell Cycle. 2005;4:838–845.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633–637.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Hamerlik P, Stockhausen MT, et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene. 2010;29:5095–5102.
   PubMed Web of Science ®Google Scholar
• Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26:7773–7779.
   PubMed Web of Science ®Google Scholar
• Burrell RA, McGranahan N, Bartek J, et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338–345.
   PubMed Web of Science ®Google Scholar
• Bartek J, Mistrik M, Bartkova J. Thresholds of replication stress signaling in cancer development and treatment. Nat Struct Mol Biol. 2012;19:5–7.
   PubMed Web of Science ®Google Scholar
• Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123:473–484.
   PubMed Web of Science ®Google Scholar
• Holgado BL, Guerreiro Stucklin A, Garzia L, et al. Tailoring medulloblastoma treatment through genomics: making a change, one subgroup at a time. Annu Rev Genomics Hum Genet. 2017;18:143–166.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17:484–495.
   PubMed Web of Science ®Google Scholar
• Wang X, Ramaswamy V, Remke M, et al. Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. Neurosurgery. 2013;60(Suppl 1):57–63.
   PubMedGoogle Scholar
• Northcott PA, Korshunov A, Pfister SM, et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol. 2012;8:340–351.
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol. 2007;4:295–304.
   PubMedGoogle Scholar
• Soderberg-Naucler C, Johnsen JI. Cytomegalovirus infection in brain tumors: A potential new target for therapy? Oncoimmunology. 2012;1:739–740.
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C, Johnsen JI. Cytomegalovirus in human brain tumors: role in pathogenesis and potential treatment options. World J Exp Med. 2015;5:1–10.
   PubMedGoogle Scholar
• Baumgarten P, Michaelis M, Rothweiler F, et al. Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics. Neuro Oncol. 2014;16:1469–1477.
   PubMed Web of Science ®Google Scholar
• Sardi I, Lucchesi M, Becciani S, et al. Absence of human cytomegalovirus infection in childhood brain tumors. Am J Cancer Res. 2015;5:2476–2483.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Ito Y, Isomura H, et al. Lack of presence of the human cytomegalovirus in human glioblastoma. Mod Pathol. 2014;27:922–929.
   PubMed Web of Science ®Google Scholar
• Cojoc M, Mabert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015;31:16–27.
   PubMed Web of Science ®Google Scholar
• Turi Z, Senkyrikova M, Mistrik M, et al. Perturbation of RNA Polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells. Cell Cycle. 2018;17:92–101.
   PubMed Web of Science ®Google Scholar
• Lukas C, Bartkova J, Latella L, et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res. 2001;61:4990–4993.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Bartek J, Vojtesek B, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer. 1993;29A:881–886.
   PubMed Web of Science ®Google Scholar
• Maya-Mendoza A, Moudry P, Merchut-Maya JM, et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559:279–284.
   PubMed Web of Science ®Google Scholar
• Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209:507–520.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078.
   PubMed Web of Science ®Google Scholar
• Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017;31:737–54 e6.
   PubMed Web of Science ®Google Scholar
• Gong C, Valduga J, Chateau A, et al. Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1. Oncotarget. 2018;9:15312–15325.
   PubMedGoogle Scholar
• Fornara O, Bartek J Jr., Rahbar A, et al. Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impact. Cell Death Differ. 2016;23:261–269.
   PubMed Web of Science ®Google Scholar
• Alvarez S, Diaz M, Flach J, et al. Replication stress caused by low MCM expression limits fetal erythropoiesis and hematopoietic stem cell functionality. Nat Commun. 2015;6:8548.
   PubMed Web of Science ®Google Scholar